Q-omics provides the consensus-scored TERF1P7 profile across patient tissues and cancer cell-line models. TERF1P7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TERF1P7 is differentially expressed in 10, with the highest sampling consensus in UCEC. Additionally, TERF1P7 RNA expression shows 19,223 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, UCEC, and UVM as cancer lineages where TERF1P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TERF1P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TERF1P7 survival associations across molecular data types. TERF1P7 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TERF1P7 RNA expression–survival associations across cancer types. High TERF1P7 expression shows unfavorable associations in COAD, CESC, UVM and PRAD, but favorable associations in SKCM and BLCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for TERF1P7 RNA expression.
This table summarizes TERF1P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TERF1P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TERF1P7 shows lower tumor expression in UCEC, LUSC and BRCA and higher tumor expression in LIHC, CHOL and KIRC. The UCEC box plot shows higher TERF1P7 RNA expression in normal versus tumor tissue (log2 FC = −0.484, t-test p < 0.001).
This table shows molecular features associated with TERF1P7 in patient tissues and cancer cell lines. In patient samples, TERF1P7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
